Apollo raises mighty sum for unique drug development model

British and American biotech Apollo Therapeutics has boosted its  series C financing round by $33.5 million, bringing the total amount to $260 million.

The money will be used to advance pipeline programs through clinical development and further fund Apollo’s drug discovery and development activities.

The start-up, which has a footprint in Cambridge, UK, and Boston, USA, raised $145 million in 2021, with money from Patient Square Capital among others.